OS THERAPIES INCORPORATED: 10-Q filed 2024-05-20

Name: OS THERAPIES INCORPORATED: 10-Q filed 2024-05-20
Creator: OS THERAPIES INCORPORATED

What OS THERAPIES INCORPORATED reported in its quarterly report filed 2024-05-20 (fiscal Q1 2024): 24 published measures, 51 facts as tagged in accession 0001213900-24-045141.

This filing

Form: 10-Q (quarterly report)
Filed: 2024-05-20
Fiscal period: fiscal Q1 2024
Accession: 0001213900-24-045141 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All OS THERAPIES INCORPORATED filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2024-03-31	1,048,924	USD
At 2023-12-31	798,082	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2024-03-31	26,555,381	USD
At 2023-12-31	24,814,297	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2024-03-31	-25,506,457	USD
At 2023-12-31	-24,016,215	USD
At 2023-03-31	-18,735,447	USD
At 2022-12-31	-17,557,228	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-1,458,992	USD	91
2023-01-01 to 2023-03-31	-1,846,969	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-641,729	USD	91
2023-01-01 to 2023-03-31	-428,186	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	702,978	USD	91
2023-01-01 to 2023-03-31	610,775	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-03-31	1,145	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2024-03-31	-31,008,429	USD
At 2023-12-31	-29,518,187	USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-630,232	USD	91
2023-01-01 to 2023-03-31	-1,048,031	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2024-03-31	1,041,569	USD
At 2023-12-31	790,032	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	828,760	USD	91
2023-01-01 to 2023-03-31	798,938	USD	90

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2024-03-31	26,455,381	USD
At 2023-12-31	24,714,297	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2024-03-31	2,799,120	USD
At 2023-12-31	2,715,399	USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

Period	Value	Unit	Days
At 2024-03-31	7,355	USD
At 2023-12-31	8,050	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	361,809	USD	91
2023-01-01 to 2023-03-31	753,784	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2024-03-31	11,982,082	shares
At 2023-12-31	10,680,000	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2024-03-31	100,231	USD
At 2023-12-31	38,982	USD
At 2023-03-31	355,214	USD
At 2022-12-31	171,480	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2024-03-31	5,489,990	USD
At 2023-12-31	5,489,990	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2024-03-31	162,500	USD
At 2023-12-31	162,500	USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-1,490,242	USD	91
2023-01-01 to 2023-03-31	-1,878,219	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	268,423	USD	91
2023-01-01 to 2023-03-31	294,247	USD	90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	695	USD	91
2023-01-01 to 2023-03-31	100	USD	90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	-828,760	USD	91
2023-01-01 to 2023-03-31	-798,938	USD	90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2024-01-01 to 2024-03-31	41,453	USD	91
2023-01-01 to 2023-03-31	446,028	USD	90

Inspect the source

Entity: OS THERAPIES INCORPORATED / CIK 0001795091
Captured: 2026-09-21T17:27:44.173Z
SEC response SHA-256: 669bcadf50e4b68c7e4f2d8dd624a583f81eb742fe94fe68568915c3f814e025

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001795091.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))